Results 201 to 210 of about 86,556 (273)

How can actuarial science contribute to the field of health technology assessment? An interdisciplinary perspective. [PDF]

Int J Technol Assess Health Care
Espinosa O, Drummond M, Russo E, Williams D, Wix D.   +4 more
europepmc   +1 more source

Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy. [PDF]

Cureus
Duesberg MS, Schiller G.
europepmc   +1 more source

Artificial Intelligence and the Transformation of Cell and Gene Therapy Development. [PDF]

Pharmaceutics
Auclair JR, Joung J, Singh MA, Debauve G, Singh R.   +4 more
europepmc   +1 more source

A budget impact analysis of gene therapy for sickle cell disease: an updated analysis. [PDF]

Blood Adv
DeMartino PC, Haag MB, Caughey AB, Roth JA.   +3 more
europepmc   +1 more source

Body composition in early pubescent children with obesity: effects following 1 year of nonintervention.

J Appl Physiol (1985)
Babb TG, Wilhite DP, Martinez-Fernandez T, Liu Y, Gupta OT, Barlow S, Bhammar DM.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Variable annuity pricing, valuation, and risk management: a survey

Scandinavian Actuarial Journal, 2022
Variable annuity is arguably the most complex individual retirement planning product in the financial market. Its intricacy stems from a variety of product features including investment options, guaranteed benefits, withdrawal options, etc. In many ways,
Runhuan Feng, Guojun Gan
exaly   +2 more sources

What's Wrong with Annuity Markets?

Finance and Economics Discussion Series, 2021
We show that the supply of life annuities in the U.S. is constrained by interest rate risk. We identify this effect using annuity prices offered by U.S.
Stéphane Verani, P. Yu
semanticscholar   +1 more source